$SLS News Article - SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast https://marketwirenews.com/news-releases/sell...10244.html
(0)
(0)
SELLAS Life Sciences Group, Inc. (SLS) Stock Research Links